SyntheticMR’s software solution SyMRI receives regulatory approval in Japan

SyntheticMR announced today that their quantitative imaging software solution SyMRi has received regulatory approval in Japan and can now be sold on this market.

“We are proud to bring our SyMRI software to the Japanese market” says Ulrik Harrysson, CEO, SyntheticMR. “We have an established customer base in Japan currently using the product for research. Now we are excited to be able to offer SyMRI for clinical use on the Japanese market. We know there are many healthcare providers that are looking forward to utilize our technology to speed up their current workflow and add additional information to aid in diagnosis.”

SyMRI provides multiple contrast weighted images and quantitative information about the patient in a single 5-6-minute scan, enabling users to speed up their imaging workflow and add objective decision support to their practice. 

For additional information, please contact Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87 ulrik.harrysson@syntheticmr.com.

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB’s product SyMRI® delivers multiple contrast images and quantitative data from a single 6-minute scan. The product is available in different packages. SyMRI IMAGE supports faster MRI workflows and improved patient throughput. SyMRI NEURO delivers automatic segmentation of brain tissue, supporting objective decision support. SyMRI is CE-marked and FDA 510(k) cleared. SyMRI is a registered trademark in Europe and in the USA. SyntheticMR is listed on the Spotlight Stock Market in Stockholm, Sweden. For additional information, please visit www.syntheticmr.com.

This information is information that SyntheticMR AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on May 18 2020.